Laurel H Messer1, Bruce A Buckingham2, Fran Cogen3, Mark Daniels4, Greg Forlenza1, Rabab Z Jafri5, Nelly Mauras6, Andrew Muir7, R Paul Wadwa1, Perrin C White8, Steven J Russell9, Edward R Damiano10,11, Firas H El-Khatib10,11, Katrina J Ruedy12, Courtney A Balliro9, Zoey Li12, Martin Chase Marak12, Peter Calhoun12, Roy W Beck12. 1. Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA. 2. Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine, Palo Alto, California, USA. 3. Department of Endocrinology and Diabetes, Children's National Medical Center, Washington, District of Columbia, USA. 4. Endocrinology and Diabetes Division, Children's Hospital of Orange County, Orange, California, USA. 5. Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA. 6. Division of Endocrinology, Diabetes & Metabolism, Department of Pediatrics, Nemours Children's Health System, Jacksonville, Florida, USA. 7. Department of Pediatrics, Emory University, Atlanta, Georgia, USA. 8. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 9. Diabetes Research Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 10. Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA. 11. Beta Bionics, Concord, Massachusetts, USA. 12. JAEB Center for Health Research, Tampa, Florida, USA.
Abstract
Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) in youth 6-17 years old with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized, controlled trial, 165 youth with T1D (6-17 years old; baseline HbA1c 5.8%-12.2%; 35% using multiple daily injections, 36% using an insulin pump without automation, 4% using an insulin pump with low glucose suspend, and 25% using a hybrid closed-loop system before the study) were randomly assigned 2:1 to use BP (n = 112) with insulin aspart or insulin lispro (BP group) or to a control group (n = 53) using their personal standard care insulin delivery (SC group) plus real-time continuous glucose monitoring (CGM). The primary outcome was HbA1c at 13 weeks. Results: Mean HbA1c decreased from 8.1% ± 1.2% at baseline to 7.5% ± 0.7% at 13 weeks with BP versus 7.8% ± 1.1% at both baseline and 13 weeks with SC (adjusted difference = -0.5%, 95% CI -0.7% to -0.2%, P < 0.001). Participants with baseline HbA1c ≥9.0% (n = 34) decreased mean HbA1c from 9.7% ± 0.8% to 7.9% ± 0.6% after 13 weeks with BP compared with 9.7% ± 0.5% to 9.8% ± 0.8% with SC. Over 13 weeks, mean time in range (TIR) 70-180 mg/dL increased by 10% (2.4 h per day) and mean CGM glucose was reduced by 15 mg/dL with BP compared with SC (P < 0.001). Analyses of time >180 mg/dL, time >250 mg/dL, and standard deviation of CGM glucose favored BP (P < 0.001). Time <54 mg/dL was low at baseline (median 0.2%) and not significantly different between groups over 13 weeks (P = 0.24). A severe hypoglycemia event occurred in 3 (2.7%) participants in the BP group and in 1 (1.9%) in the SC group. Conclusions: In youth 6-17 years old with T1D, use of insulin-only configuration of BP improved HbA1c, TIR, and hyperglycemic metrics without increasing CGM-measured hypoglycemia compared with standard of care. Improvement in glycemic metrics was most pronounced in participants with high baseline HbA1c levels. Clinical Trial Registry: clinicaltrials.gov; NCT04200313.
Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) in youth 6-17 years old with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized, controlled trial, 165 youth with T1D (6-17 years old; baseline HbA1c 5.8%-12.2%; 35% using multiple daily injections, 36% using an insulin pump without automation, 4% using an insulin pump with low glucose suspend, and 25% using a hybrid closed-loop system before the study) were randomly assigned 2:1 to use BP (n = 112) with insulin aspart or insulin lispro (BP group) or to a control group (n = 53) using their personal standard care insulin delivery (SC group) plus real-time continuous glucose monitoring (CGM). The primary outcome was HbA1c at 13 weeks. Results: Mean HbA1c decreased from 8.1% ± 1.2% at baseline to 7.5% ± 0.7% at 13 weeks with BP versus 7.8% ± 1.1% at both baseline and 13 weeks with SC (adjusted difference = -0.5%, 95% CI -0.7% to -0.2%, P < 0.001). Participants with baseline HbA1c ≥9.0% (n = 34) decreased mean HbA1c from 9.7% ± 0.8% to 7.9% ± 0.6% after 13 weeks with BP compared with 9.7% ± 0.5% to 9.8% ± 0.8% with SC. Over 13 weeks, mean time in range (TIR) 70-180 mg/dL increased by 10% (2.4 h per day) and mean CGM glucose was reduced by 15 mg/dL with BP compared with SC (P < 0.001). Analyses of time >180 mg/dL, time >250 mg/dL, and standard deviation of CGM glucose favored BP (P < 0.001). Time <54 mg/dL was low at baseline (median 0.2%) and not significantly different between groups over 13 weeks (P = 0.24). A severe hypoglycemia event occurred in 3 (2.7%) participants in the BP group and in 1 (1.9%) in the SC group. Conclusions: In youth 6-17 years old with T1D, use of insulin-only configuration of BP improved HbA1c, TIR, and hyperglycemic metrics without increasing CGM-measured hypoglycemia compared with standard of care. Improvement in glycemic metrics was most pronounced in participants with high baseline HbA1c levels. Clinical Trial Registry: clinicaltrials.gov; NCT04200313.
Authors: Parul J Patel; Kari Benasi; Gina Ferrari; Mark G Evans; Satya Shanmugham; Darrell M Wilson; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2013-10-03 Impact factor: 6.118
Authors: Steven J Russell; Roy W Beck; Edward R Damiano; Firas H El-Khatib; Katrina J Ruedy; Courtney A Balliro; Zoey Li; Peter Calhoun; R Paul Wadwa; Bruce Buckingham; Keren Zhou; Mark Daniels; Philip Raskin; Perrin C White; Jane Lynch; Jeremy Pettus; Irl B Hirsch; Robin Goland; John B Buse; Davida Kruger; Nelly Mauras; Andrew Muir; Janet B McGill; Fran Cogen; Jill Weissberg-Benchell; Jordan S Sherwood; Luz E Castellanos; Mallory A Hillard; Marwa Tuffaha; Melissa S Putman; Mollie Y Sands; Gregory Forlenza; Robert Slover; Laurel H Messer; Erin Cobry; Viral N Shah; Sarit Polsky; Rayhan Lal; Laya Ekhlaspour; Michael S Hughes; Marina Basina; Betul Hatipoglu; Leann Olansky; Amrit Bhangoo; Nikta Forghani; Himala Kashmiri; Francoise Sutton; Abha Choudhary; Jimmy Penn; Rabab Jafri; Maria Rayas; Elia Escaname; Catherine Kerr; Ruby Favela-Prezas; Schafer Boeder; Subbulaxmi Trikudanathan; Kristen M Williams; Natasha Leibel; M Sue Kirkman; Kate Bergamo; Klara R Klein; Jean M Dostou; Sriram Machineni; Laura A Young; Jamie C Diner; Arti Bhan; J Kimberly Jones; Matthew Benson; Keisha Bird; Kimberly Englert; Joe Permuy; Kristina Cossen; Eric Felner; Maamoun Salam; Julie M Silverstein; Samantha Adamson; Andrea Cedeno; Seema Meighan; Andrew Dauber Journal: N Engl J Med Date: 2022-09-29 Impact factor: 176.079
Authors: Marc D Breton; Lauren G Kanapka; Roy W Beck; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa Schoelwer; Katrina J Ruedy; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Mary Oliveri; Craig C Kollman; Betsy B Dokken; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Daniel Cherñavvsky; R Paul Wadwa Journal: N Engl J Med Date: 2020-08-27 Impact factor: 91.245
Authors: Julia Ware; Charlotte K Boughton; Janet M Allen; Malgorzata E Wilinska; Martin Tauschmann; Louise Denvir; Ajay Thankamony; Fiona M Campbell; R Paul Wadwa; Bruce A Buckingham; Nikki Davis; Linda A DiMeglio; Nelly Mauras; Rachel E J Besser; Atrayee Ghatak; Stuart A Weinzimer; Korey K Hood; D Steven Fox; Lauren Kanapka; Craig Kollman; Judy Sibayan; Roy W Beck; Roman Hovorka Journal: Lancet Digit Health Date: 2022-03-07
Authors: Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2017-01-30 Impact factor: 6.118
Authors: Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2018-12-26 Impact factor: 6.118
Authors: Jane Lynch; Lauren G Kanapka; Steven J Russell; Edward R Damiano; Firas H El-Khatib; Katrina J Ruedy; Courtney Balliro; Peter Calhoun; Roy W Beck Journal: Diabetes Technol Ther Date: 2022-10 Impact factor: 7.337